

1 **Relationship between Polyunsaturated Fatty Acids and Inflammation:**
2 **evidence from cohort and Mendelian randomization analyses**

3 Daisy C. P. Crick^{1,2*}, Sarah Halligan^{3,4}, George Davey Smith^{1,2}, Golam M. Khandaker^{1,2,5,6,7*}
4 & Hannah J. Jones^{1,2,5,7*}

5

6 1. MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School,
7 University of Bristol, Bristol, UK

8 2. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

9 3. Department of Psychology, University of Bath, Bath, UK

10 4. Department of Psychiatry and Mental Health, University of Cape Town, South Africa

11 5. NIHR Bristol Biomedical Research Centre, Bristol, UK

12 6. Avon and Wiltshire Mental Health Partnership NHS Trust, Bristol, UK

13 7. Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School,
14 University of Bristol, Bristol, UK

15 * Joint senior authors

16

17 Author for correspondence: Daisy Crick, University of Queensland, Institute of Molecular
18 Bioscience. Email: ugdcrick@uq.edu.au

19

20 **Word Count: Abstract: 190/200, Main body 3752/5000**

21

* Author for correspondence: Daisy Crick, University of Queensland, Institute of Medical Bioscience, St Lucia, 4072, Australia.
Email: ugdcrick@uq.edu.au

22 Dietary polyunsaturated fatty acids (PUFAs) are thought to influence the risk of various
23 chronic diseases by modulating systemic inflammation. Omega-3 and omega-6 FAs are
24 thought to have anti- and pro-inflammatory roles, respectively, but it is unclear whether
25 these associations are causal. We tested associations of PUFAs with three blood-based
26 biomarkers of systemic inflammation, namely C-reactive protein (CRP), glycoprotein acetyls
27 (GlycA) and interleukin 6 (IL-6), in a population cohort (n=2748) and using Mendelian
28 randomization analysis (a genetic causal inference method). We provide consistent evidence
29 that omega-6 PUFAs increase GlycA levels, but omega-3 FAs do not lower levels of
30 inflammatory markers. Additionally, we found that a higher omega-6:omega-3 ratio
31 increases levels of all three inflammatory markers; CRP (mean difference=0.17; 95% CI=0.13,
32 0.20), GlycA (mean difference=0.16; 95% CI=0.13, 0.20) and IL-6 (mean difference=0.19; 95%
33 CI=0.15, 0.22) in the cohort analysis. Our findings suggest that future public health
34 messaging should encourage reducing the consumption of omega 6 FAs and maintaining a
35 healthy balance between omega 3 and omega 6 FAs, rather than focusing on omega-3 FA
36 supplementation. This is because dietary omega-3 supplementation alone is unlikely to help
37 reduce systemic inflammation or inflammation-related disease.

38

39 **Keywords:** Systemic Inflammation; C-reactive Protein, Glycoprotein Acetyls, Interleukin 6,
40 Polyunsaturated fatty acids, Omega-3; Omega-6; Mendelian Randomization, ALSPAC.

41

42

43

44

45

46

47

48 **1. Introduction**

49 Non-communicable diseases (NCDs) are the main cause of global mortality, representing
50 71% of deaths worldwide². As such, their prevention remains a key challenge. Systemic low-
51 grade inflammation, reflected by elevated concentrations of markers of inflammation such
52 as cytokines (e.g. interleukin-6 (IL-6)) and acute phase proteins (e.g. C-reactive protein
53 (CRP)), has been implicated in the pathophysiology of many NCDs from cardiovascular
54 disease to depression³⁻¹². Therefore, inflammation appears a promising target for their
55 treatment and prevention.

56 Polyunsaturated fatty acids (PUFAs), are proposed to influence levels of systemic
57 inflammation¹³. There are two main families of PUFAs which are essential for many
58 metabolic processes: Omega-3 (n-3)^{14, 15}; and Omega-6 (n-6)¹⁵, along with eicosatetraenoic
59 acid and docosahexaenoic (DHA) acid (both n-3 PUFAs), and arachidonic acid (ARA; an n-6
60 PUFA) linked most clearly to various essential physiological processes. These processes
61 include maintaining cell membrane structural integrity, hormone synthesis, regulation of
62 gene expression, and supporting brain and nervous system functioning¹⁶. Some PUFAs such
63 as ARA can come from both exogenous sources (such as meat and egg products) and
64 endogenous sources. This is where the PUFAs can be synthesized from their metabolomic
65 precursors: α -linolic acid (ALA; an n-3 PUFA) and linolic acid (LA: an n-6 PUFA), through
66 desaturation and elongation reactions¹⁷. In comparison, humans cannot synthesise LA or
67 ALA and therefore they must be acquired through dietary consumption¹⁸ such as vegetable
68 oils (for LA) and seed oils (ALA).

69

70 There is some evidence that N-3 PUFAs have anti-inflammatory effects and protect against
71 the severity/occurrence of inflammation-related conditions^{19, 20}. For example, there are
72 suggestions that fatty fish consumption can reduce the probability of death from a heart
73 attack^{21, 22}. This is attributed to n-3 PUFAs ability to alter the production of prostaglandins,
74 which subsequently reduce inflammation (measured by the reduced concentration of
75 circulating inflammatory biomarkers in the blood)²³⁻²⁶. However, clinical trials investigating
76 the effects of n-3 supplementation have yielded contradictory results^{27, 28} regarding its
77 effect on systemic inflammation. Dietary supplementation studies have reported that the
78 consumption of n-6 PUFAs, which are typically thought to be pro-inflammatory, did not
79 affect the concentration of inflammatory markers such as IL-6 or CRP^{23, 29-31}.

80 A meta-analysis of 14 clinical trials that included total 1,35,291 participants found that
81 omega-3 supplementation reduced the risk of major adverse cardiovascular event,
82 cardiovascular death and myocardial infarction³². In contrast, an RCT study investigating
83 dietary intake and mortality in 3114 men with angina, found that risk of cardiac death was
84 higher among individuals advised to eat oily fish or to take fish oil compared to those not
85 advised to do so. Additionally, RCTs investigating supplementation in patients to treat other
86 inflammation-related NCDs found similarly inconsistent results (e.g.^{33, 34}). However, these
87 studies did not directly test the effect of fatty acids on inflammation levels and the
88 inconsistent findings of the RCTs cast doubt on the posited immune modulatory effect of n-
89 3 and n-6. Further, the contradictory results also raise questions of whether PUFAs *causally*
90 influence concentrations of biomarkers of inflammation or whether the observed
91 associations are the result of residual confounding.

92 Both n-3 and n-6 PUFAs are metabolized by the same enzymes and compete for
93 desaturation and elongation. This means it is plausible that n-6 PUFAs act as competitive
94 inhibitors of n-3 PUFAs and thus reduce the amount of end-product n-3 PUFAs that can be
95 synthesised³⁵. As a result, a lower concentration of n-3 PUFAs could reduce their anti-
96 inflammatory effects³⁶⁻³⁸. In contrast, a lower plasma n-6:n-3 ratio may result in higher
97 levels of end-product n-3 PUFAs which would subsequently lower concentrations of
98 inflammatory markers leading to beneficial effects on health outcomes³⁹. As such, further
99 research to understand the importance of the n-6:n-3 ratio on levels of inflammation and its
100 impact on the occurrence of NCDs is of public health concern.

101 We examined whether circulating levels of PUFAs are associated with systemic biomarkers
102 of inflammation using (1) data from a population-based prospective birth cohort and (2)
103 two-sample Mendelian randomization (MR), a causal inference method that uses genetic
104 variants as proxies to examine whether the association between a risk factor and a disease
105 outcome is likely to be causal or result of residual confounding or reverse causation⁴⁰.

106 We investigated the effects on inflammatory markers of specific n-3 and n-6 PUFAs which
107 play a role in key metabolic processes. These are the long-chain n-3 PUFA DHA and the
108 short-chain n-6 PUFA LA which appear at opposite ends of the biosynthesis pathways (see
109 figure 1; adapted from Videla et al.¹). In addition, for a greater interrogation of the PUFA-
110 inflammation relationship, we used measures of total n-3 PUFAs, total n-6 PUFAs and the
111 ratio of total n-6 PUFAs:total n-3 PUFAs (referred hereafter as the total n-6:n-3 ratio) as
112 exposures. As outcomes we used three biomarkers for systemic inflammation, namely CRP,
113 IL-6, and Glycoprotein Acetyls or GlycA (a novel composite biomarker of inflammatory acute
114 phase proteins^{41, 42}).

115 **2. Results**

116 2.1 Findings from Population-based Cohort Analyses

117 Table 1 presents the median/range for PUFA levels (DHA, LA, total n-3 PUFAs and total n-6
118 PUFAs) and inflammatory biomarker levels (IL-6, CRP and GlycA) from participants of the
119 Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort at age 24y. There
120 was no difference between the complete-case and imputed results (eTable 15) and
121 distributions of observed and imputed characteristics are presented in supplementary
122 eTable 16. The results of the below associations are presented in eTable17 and eTable 18.

123 *2.1.1 Associations of DHA and LA with inflammatory markers*

124 Both DHA and LA were associated with higher CRP and GlycA levels, but lower IL-6 levels at
125 24y after adjusting for potential confounders relating to sex, substance use, social economic
126 position, and maternal pregnancy health (Figure 2).

127 *2.1.2 Associations of total n-3 and n-6 PUFAs with inflammatory markers*

128 Total n-3 and n-6 PUFAs were associated with higher GlycA levels, but lower IL-6 levels at
129 24y after adjusting for potential confounders. Total n-6 was associated with higher CRP
130 levels but there was no strong evidence of association between total n-3 PUFAs and CRP
131 (Figure 2).

132 *2.1.3 Associations between total n-6:n-3 ratio and inflammatory markers*

133 The total n-6:n-3 ratio was associated with higher levels of all three inflammatory markers
134 (CRP, GlycA and IL-6) at age 24y after adjusting for potential confounders (Figure 2).

135 *2.1.4 Sex Specific Associations between PUFAs and Inflammatory Markers*

136 In sex-stratified analyses, the n-6:n-3 ratio was associated with higher levels of all three
137 inflammatory markers in both sexes (Figure 3). PUFAs were also associated with higher
138 GlycA in males and females. The effects of all PUFAs on CRP and IL-6 levels attenuated to
139 the null in males. In females, PUFAs were associated with higher CRP but lower IL-6 levels,
140 which mirrored findings from the whole cohort analysis.

141 2.2 Results for Mendelian Randomization Analyses

142 We used two-sample MR to assess evidence for causality using publicly available summary-
143 level data from European population GWAS of the PUFAs⁴³, GlycA⁴⁴, CRP⁴⁵ and IL-6⁴⁶. See
144 eMethods for further information.

145 Tests investigating instrument validity, described in the methods section, indicated that
146 instruments were unlikely to be subject to weak instrument bias (see eResults).

147 2.2.1. Potential causal effect of DHA on inflammatory markers

148 We observed no strong evidence of effect of DHA levels on CRP (IVW estimate: 0.03; 95%
149 CI: -0.01, 0.09), GlycA (IVW estimate: 0.01; 95% CI: -0.06, 0.07) or IL-6 (IVW estimate: 0.07;
150 95% CI: -0.20, 0.07). These results were largely consistent across sensitivity analyses using
151 MR methods that make different assumptions about instrument validity (MR-egger,
152 weighted median and weighted mode) (Figure 4).

153 2.2.2. Potential causal effect of LA on inflammatory markers

154 We observed no strong evidence of effect of LA levels on CRP (IVW estimate: -0.10; -0.10,
155 0.09) or IL-6 (IVW estimate: 0.02; -0.05, 0.08). We observed estimates suggesting that higher
156 LA levels cause higher GlycA levels (IVW estimate: 0.25; 0.15, 0.35). Other than in the
157 analysis investigating the effect of LA levels on CRP, results were consistent across MR
158 sensitivity methods (Figure 4).

159 *2.2.3. Potential causal effect of total n-3 PUFA levels on inflammatory markers*

160 Higher total n-3 PUFA levels were associated with higher CRP (IVW estimate: 0.09; 0.03,
161 0.16) and GlycA (IVW estimate: 0.12; 0.04, 0.21) levels. We observed no effect of total n-3
162 PUFA levels on IL-6 (IVW estimate: -0.04; -0.09, 0.02). Results attenuated to the null in all
163 MR sensitivity analyses of total n-3 PUFA levels and GlycA (Figure 4).

164 *2.2.4. Potential causal effect of total n-6 PUFA levels on inflammatory markers*

165 We observed no strong evidence of effect of total n-6 PUFA levels on CRP (IVW estimate:
166 0.04, -0.05, 0.13) or IL-6 (IVW estimate: -0.08; -0.03, 0.04). We did observe estimates that
167 suggest that higher n-6 PUFA levels cause higher GlycA levels (IVW estimate: 0.25; 0.16,
168 0.34) with estimates consistent in sensitivity analyses with the exception of the weighted
169 mode analysis (Figure 4).

170

171 *2.3 Evidence of pleiotropy and heterogeneity*

172 MR Egger intercepts and tests for heterogeneity between the SNP effect estimates are
173 presented in eTable 19. There was no strong evidence of pleiotropic effect as detected by
174 the MR-Egger intercept for the association between PUFA levels and any biomarker with the
175 exception of the association between total n-3 levels and GlycA. Findings were fairly
176 consistent with results using the MR-PRESSO test for pleiotropy (eTable20). There was
177 strong evidence of heterogeneity in all analyses apart from in analyses of total n-3 and LA
178 levels and IL-6.

179

180 *2.4 Findings on the potential impact of methodological biases in MR results*

181 MR-Lap⁴⁷ was used to assess potential biases in observed effect estimates due to sample
182 overlap between the fatty acid, CRP and GlycA GWAS. Results suggested that the majority of

183 analyses were largely unaffected by winner's curse and weak instrument biases introduced
184 through sample overlap. The corrected effect differed from the observed effect only for
185 analysis investigating the effect of total n-6 PUFAs on GlycA and CRP levels. In both
186 instances, the observed effect estimate was in the same direction as the corrected estimate
187 and the confidence intervals did not cross the null but were wider. See eResults for further
188 information.

189

190 2.5 Results from MR Analysis Focusing on Specific Genes

191 The *FADS* gene cluster and *ELOVL2* gene encode key desaturase and elongase enzymes
192 respectively and are involved in the n-3 and n-6 fatty acid biosynthesis pathways. Therefore,
193 we conducted a complementary and mechanistically informative MR analysis by using only
194 genetic instruments from within or close to the *FADS* gene cluster (*FADS1*, *FADS2* and
195 *FADS3*) and *ELOVL2* gene with the aim of reducing the impact of other pleiotropic pathways.
196 MR analyses using SNPs from the *FADS* gene region showed that DHA increases CRP levels
197 (IVW estimate: =0.04; 95% CI=0.01, 0.07), but LA decreases CRP levels (IVW estimate: =-
198 0.14; -0.20, -0.07). *FADS* instrumented DHA and LA had no effect on GlycA and (where
199 testable) IL-6. There was no evidence of a causal effect of any SNPs from the *ELOVL2* gene
200 on GlycA, CRP, or IL-6. See eResults for further information.

201

202 2.6 Results from analyses exploring heterogeneity of MR instruments

203 Given that evidence of associations between the PUFAs and GlycA were largely consistent
204 across cohort and MR analyses, we used MR-Clust⁴⁸ to investigate whether there were
205 distinct clusters of SNPs effects driving the heterogeneity observed in the MR analysis with

206 GlycA levels as the outcome. In the analysis using genetic instruments for LA, total n-3
207 PUFAs and total n-6 PUFAs, all clusters were positively associated with GlycA which is
208 consistent with the main results. However, for DHA, there were two SNP clusters showing a
209 positive association with GlycA and one cluster showing a negative association with GlycA
210 levels. This could explain the observed null results between DHA and GlycA found in the
211 main analysis. See eResults, eTable 26, and eFigures 3-6 for further information.

212 We obtained functional annotations of the genomic loci associated for all identified clusters
213 from FUMAGWAS (<https://fuma.ctglab.nl>) and investigated in which tissues the genes were
214 up- or down-regulated (eFigures 7-10). Overall, most differentially expressed genes were
215 expressed in the liver. For the association between DHA and GlycA, tissues with most
216 differentially expressed genes were: liver (cluster 1), breast (cluster 2) and kidneys (cluster
217 5). For the association between LA and GlycA, tissues with most differentially expressed
218 genes were: liver (clusters 1 and 2) and kidneys (cluster 4). For the association between total
219 omega-3 and GlycA, most differentially expressed genes in both clusters 2 and 6 were in
220 liver. Finally, for the association between total omega-6 and GlycA, most differentially
221 expressed genes were in kidneys (cluster 1) and liver (cluster 4).

222

223 2.7 Multivariable MR investigating the direct effects of total omega-3 and total omega-6 on
224 inflammatory markers

225 We conducted a Multivariable Mendelian Randomization (MVMR) analysis to estimate the
226 individual direct causal effects of total n-3 and n-6 PUFAs on the biomarkers of inflammation
227 independently of each other. We observed a positive direct effect of total n-6 PUFA levels
228 on both GlycA (IVW estimate: 0.33; 0.19, 0.47) and CRP levels (IVW estimate: 0.20; 0.01,

229 0.39), but not IL-6 levels (IVW estimate: 0.17; -0.17, 0.50), after controlling for the effect of
230 n-3 PUFAs. There was no direct effect of total n-3 PUFA levels on GlycA (IVW estimate: 0.06;
231 -0.05, 0.16), CRP (IVW estimate:0.03; -0.06, 0.12) or IL-6 (IVW estimate: -0.18; -0.49, 0.14)
232 levels after controlling for the effect of n-6 PUFAs. This suggests that the effect of total n-3
233 PUFAs on CRP levels found in the univariable MR analysis are not independent of the effect
234 of n-6, and may be a result of pleiotropy (Figure 5). See eResults for further information on
235 MVMR analysis.

236

237 **3. Discussion**

238 By combining complementary cohort and genetic analyses, we provide greater insight into
239 the relationships between dietary PUFAs and systemic inflammatory markers. Our analyses
240 of population cohort data show a consistent effect of the n-6:n-3 ratio on higher levels of all
241 three inflammatory markers in the total sample and in males and females separately.
242 However, the picture appears to be more complex when we consider total or individual FA
243 levels. For instance, total n-3 FAs levels which are thought to be anti-inflammatory are not
244 associated with CRP levels. Similarly, n-6 (thought to be pro-inflammatory) as well as n-3
245 PUFAs are associated with an increase in GlycA levels, but a decrease in IL-6.

246 Subsequent genetic analyses shed light into the complex nature of these associations
247 including the important issue of causality. First, MR results showing a potentially causal
248 effect of total n-3 PUFAs on higher circulating CRP and GlycA levels contrast the presumed
249 anti-inflammatory effect of n-3 PUFAs, and argues against the widespread use of n-3
250 supplementation aimed at improving health by reducing inflammation-related disease risk.
251 Second, our MR results confirm that total n-6 and LA increase GlycA (a pro-inflammatory

252 marker), suggesting a pro-inflammatory effects of these FAs. The importance of n-6 FAs with
253 regards to modulating inflammation, rather than n-3 FAs, was also highlighted by our
254 MVMR analysis which provided evidence for a direct causal effect of total n-6 FAs increasing
255 CRP and GlycA levels after accounting for the effect of total n-3 PUFA levels. In contrast, no
256 independent effect on inflammatory marker levels was observed for total n-3 FAs.

257 Results from our further MR analyses using genetic variants within/nearby a key gene
258 involved in fatty acid metabolism (*FADS* gene cluster), indicate that several PUFA-
259 inflammatory marker associations may result from pleiotropic effects of FA-related genetic
260 variants, rather than the effect of FA biosynthesis. These include the effect of LA on GlycA,
261 effect of total n-3 PUFAs on CRP and GlycA, and effect of total n-6 PUFAs on GlycA. Our
262 approach of investigating the effect of specific genes within the PUFA biosynthesis pathway
263 is similar to recent work by Haycock *et al*⁴⁹ who investigated the effect of *FAD1* and *FAD2*
264 genes on cancer. They reported that genetically elevated PUFA desaturase activity,
265 instrumented by one SNP (rs174546), was associated with higher risk of colorectal and lung
266 cancer. Future research should investigate whether desaturase activity promotes certain
267 cancer risk through increased inflammation.

268 N-3 and n-6 PUFAs act as competitive inhibitors disrupting each other's desaturation and
269 elongation³⁶. Therefore, a greater concentration of n-6 PUFAs would result in a fewer
270 number of endpoint n-3 PUFAs being synthesized. This could be one explanation for the lack
271 of an anti-inflammatory effect of n-3 PUFAs in our work. This may also explain our finding of
272 positive associations between total n-6:n-3 PUFA levels and all three inflammatory marker
273 levels in our cohort analysis.

274 A higher n-6:n-3 ratio is thought to promote the pathogenesis of inflammation-related NCDs
275 such as cardiovascular disease, arthritis and asthma⁵⁰, and a meta-analysis of RCTs found
276 that supplementation of a low n-6:n-3 PUFA ratio inducing diet decreased concentrations of
277 inflammatory markers such as tumor necrosis factor- α and IL-6⁵¹. Therefore, it is possible
278 that n-6:n-3 PUFAs ratio is more important than concentrations of individual PUFAs with
279 regards to the risk of inflammation-related NCDs. We were unable to conduct MR for n6:n3
280 ratio because of the lack of GWAS for this measure. This should be prioritized when such
281 data becomes available in future.

282 We investigated the association between PUFAs and levels of CRP, IL-6 and GlycA, using two
283 different methods and used sensitivity analyses to address potential biases that arise in
284 epidemiological research. Despite this, we recognize several limitations. We used cross-
285 sectional analyses which means it is difficult to infer causality and we cannot determine the
286 temporal relationship between the exposure and the outcome or the directionality of this
287 relationship. Additionally, the cohort analysis was limited to only participants reported as
288 White and the GWAS used were only conducted in individuals of European descent. This
289 limits the generalizability of the results to other populations. However, the cohort analysis
290 provides useful context and provides evidence for associations between PUFA levels and
291 biomarkers of inflammation, including GlycA, which is novel.

292 DHA and LA appear at the different ends of FA biosynthesis pathways (n-3 DHA is an
293 endogenous product of a chain of desaturation and elongation reactions, while LA is a pre-
294 cursor to these reactions on the n-6 PUFA pathway). This means that a comparison between
295 the effects of these specific n-3 and n-6 PUFAs is difficult. Future large-scale, well-powered

296 GWAS of specific PUFAs across the biosynthesis pathway at comparable stages are needed
297 to help better understand this relationship.

298 There was sample overlap between the exposure and outcome GWAS data used for MR
299 analyses, which may lead to overfitting. However, recent research suggests that the bias
300 incurred through sample overlap is less substantial compared to biases produced by weak
301 instruments or winner's curse⁴⁷. These biases are unlikely to be issues for our MR analyses
302 as confirmed by various sensitivity analyses exploring these concerns specifically.

303 Heterogeneity in the two-sample MR analyses may have biased causal estimates towards
304 the null. Although we did investigate the outcome of the heterogeneity within the GlycA
305 analyses using MR-Clust, no clusters were specifically related to inflammation-related
306 processes.

307 Lastly, although the *FADS* gene cluster encodes enzymes fundamental to PUFA biosynthesis
308 suggesting that IVs within this region are more likely to satisfy MR assumptions, *FADS*
309 variants have been shown to be highly pleiotropic⁵² and do not differentiate n-3 or n-6
310 effects. As such, our gene based analyses may capture pathways to inflammation through
311 factors other than PUFAs, thus violating the exclusion-restriction assumption⁴⁰.

312 Given the popular use of n-3 PUFAs as supplements to reduce the occurrence of
313 inflammation-related NCDs^{27, 53, 54}, our results are of public health importance. Importantly,
314 our MR results suggest that n-6 PUFAs increase levels of CRP and GlycA when controlling for
315 n-3 PUFAs and that a higher total n-6:n-3 ratio increases levels of all three biomarkers. As
316 such, instead of focusing solely on n-3 PUFA consumption, public health messaging should
317 move towards encouraging a lower total n-6 PUFA consumption and to achieve a healthy
318 balance between n-3 and n-6 to help reduce the occurrence of inflammation-related NCDs.

319 However, as there is evidence that suggests that n-3 PUFA consumption is also beneficial to
320 health because of its hypotriglyceridaemic effects⁵⁵, a better understanding of the interplay
321 between n-6 and n-3 effects, as well as potential beneficial non-inflammation related
322 effects, is needed before considering implementing n-6 focussed changes to policy.

323 **4. Conclusion**

324 Our MR results suggest that higher LA and total n-6 PUFA levels increase GlycA, but not CRP
325 or IL-6 levels. Our MR results also suggest that higher total n-3 PUFA levels increase CRP and
326 GlycA levels, but do not increase IL-6 levels. We provide consistent evidence for positive
327 associations between total n-6:n-3 ratio and levels of CRP, GlycA and IL-6, indicating that the
328 ratio of total n-6:n-3 PUFAs may be more important with regards to systemic inflammation
329 than individuals PUFAs. However, these results came from cross-sectional analyses of cohort
330 data and we were unable to examine evidence of causality for the effects of total n-6:n-3
331 ratio using MR due to lack of GWAS data for total n-6:n-3 ratio. Nevertheless, our findings
332 do not support a strong anti-inflammatory effect of n-3 PUFAs from both cohort and MR
333 analyses. This finding requires further investigation given that n-3 PUFA supplementation
334 widely used to reduce inflammation and risk of inflammation-related NCDs.

335 **5. Methods**

336 5.1 Cohort Analysis

337 *5.1.1 Dataset and sample*

338 The Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort recruited
339 pregnant women resident in Avon, UK with expected dates of delivery between 1st April
340 1991 and 31st December 1992⁵⁶⁻⁵⁸. There were 14, 203 unique mothers initially enrolled in
341 the study and the initial number of pregnancies enrolled was 14,541 and 13,988 children

342 were alive at 1 year of age. When the oldest children were approximately 7 years of age, the
343 initial sample was bolstered with eligible cases who did not originally join the study. The
344 total sample size for analyses using any data collected after the age of seven is therefore,
345 14,833 unique mothers and 15,447 pregnancies which resulted in 15,658 fetuses. Of these,
346 14,901 were alive at 1 year of age. The offspring, their mothers and the mother's partners
347 are regularly followed up. Additional information on ALSPAC is presented in the supplement
348 eMethods. For eligibility criteria see the study flowchart (eFigure 1) in the supplement.
349 For this study, ALSPAC participants were included if they had outcome (CRP, IL-6 and GlycA
350 levels) and exposure (DHA, LA, total n-3 and total n-6) data at 24y. We excluded non-white
351 participants (2% of study population) and this exclusion is unlikely to make any difference to
352 the results due to low numbers of non-white individuals in the dataset. This gave a total of
353 2748 individuals (36.10% males) eligible for our analysis.

354 *5.1.2 PUFAs and inflammatory marker assays*

355 Participants fasted overnight, or >6 hours if being seen in the afternoon, before attending
356 the clinic for blood sampling at 24 years old. Blood samples were centrifuged immediately
357 to isolate plasma and stored at -80 °C. There were no freeze-thaw cycles during storage.

358 Total n-3, n-6, DHA and LA PUFA levels and plasma GlycA levels were measured using a high-
359 throughput proton (1H) Nuclear Magnetic Resonance (NMR) metabolomics platform
360 (Nightingale, UK)^{42, 59}. We also created a n-6:n-3 ratio (total n-6 PUFAs divided by total n-3
361 PUFAs). HsCRP was measured by automated particle-enhanced immunoturbidimetric assay
362 (Roche UK, UK). IL-6 was measured by enzyme-linked immunosorbent assay (OLINK, UK).
363 The samples were collected when the participants were 24 years old. Full details regarding
364 sample processing, NMR analysis, and data processing have been provided elsewhere⁶⁰⁻⁶².

365 GlycA levels ranged from 0.84 to 2.25 mmol/L, and IL-6 levels ranged from 1.82 to 10.60
366 Normalized Protein eXpression (NPX) Log2 scale. CRP had detection limits of 0.15-80mg/L
367 and measures outside this were removed. CRP levels ranged from 0.15 to 70.05 mg/L.

368 *5.1.3 Assessment of Covariates*

369 We used maternal self-reported highest educational qualification and highest occupation of
370 either parent (measures of social economic position (SEP)), maternal and paternal smoking
371 pattern during pregnancy (measures of pregnancy health), participants' sex, and
372 participants' smoking status and drinking status at age 24 as covariates. A detailed
373 description of how these variables were collected/coded is provided in the supplement
374 eMethods.

375 *5.1.4 Statistical analysis*

376 Multivariable linear regression analyses were used to examine the cross-sectional
377 associations of PUFA levels with GlycA ,CRP and IL-6 levels at age 24y. Regression models
378 were adjusted for potential confounders. CRP and IL-6 levels were not normally distributed
379 and were log-transformed. To help with the interpretation of results, we z-transformed both
380 exposure and outcome data, and so the effect estimates represent the increase in outcome
381 in standard deviation (SD) per SD increase in exposure. Primary analyses used the whole
382 sample, and in secondary analyses we stratified by sex.

383 We used multiple imputation (MI) to impute missing exposure, outcome and covariate data
384 in the eligible sample (N=2748), described in detail in the supplement eMethods.

385

386 *5.2 Two-sample Mendelian Randomisation Analysis*

387 *5.2.1 Study design and data sources*

388 Genome-wide significant single nucleotide polymorphisms (SNPs) ($P < 5.0 \times 10^{-8}$) were
389 selected as IVs for MR analyses. The SNPs were harmonized, aligning the genetic association
390 for exposure and outcome on the effect allele using the effect allele frequency (see
391 eMethods for details). Following harmonisation of the PUFA SNP instrument with the
392 corresponding outcome data (inflammatory biomarker), palindromic SNPs were removed
393 and the remaining SNPs underwent LD clumping. Steiger filtering was then applied, meaning
394 SNPs were removed if they explained more variance in the outcome than in the exposure.
395 The number of SNPs removed due to being palindromic, in linkage disequilibrium (LD) or as
396 a result of Steiger filtering for each analysis is reported in eTable 1. There were 46-58 SNPs
397 available to investigate the effect of PUFAs on GlycA levels, 17-39 SNPs available to
398 investigate the effect of PUFAs on CRP levels and 11-44 SNPs available to investigate the
399 effect of PUFAs on IL-6 levels. Harmonized SNP information for each relationship are
400 presented in eTables 2-13. See eMethods for further details on instrument selection.

401 *5.2.2 Statistical analysis*

402 For MR, the inverse variance weighted (IVW)⁶³ method was used as a primary analysis to
403 calculate effect estimates. MR-Egger, weighted median, and weighted mode methods were
404 used as sensitivity analyses as these methods make different assumptions about instrument
405 validity. Findings were considered robust if results were consistent across primary and
406 sensitivity analyses.

407 We report *F*-statistics for IVs, as a measure of instrument strength. Presence of
408 heterogeneity between the SNP effect estimates was assessed using Cochran's Q test in the
409 IVW analysis and the Rucker's Q test in the MR-Egger analyses. We used the MR-Egger
410 intercept and MR Pleiotropy Residual Sum and Outlier global test (MR-PRESSO) to

411 investigate the presence of pleiotropy. See eTable 14 for a description of MR methods and
412 sensitivity analyses used⁶⁴.

413 *5.2.3 MR-Lap analysis to investigate bias from sample overlap, weak instrument and*

414 *Winner's Curse*

415 The fatty acid GWAS, the CRP GWAS and GlycA GWAS were conducted using UKB data. This
416 sample overlap may modify biases caused by the use of weak instruments and winner's
417 curse. To overcome this, the MR-Lap method was used to assess potential bias in observed
418 effect estimates due to sample overlap, winner's curse, or weak instruments⁴⁷. Greater
419 detail of MR-Lap method is provided in eMethods.

420 *5.2.4 Additional MR analysis focusing on specific PUFA genes*

421 MR was conducted using genetic instruments (SNPs) from within or close to (+/-500 kb) the
422 *FADS* gene cluster (*FADS1*, *FADS2* and *FADS3*; chromosome 11: 61,560,452–61,659,523)
423 and *ELOVL2* gene (chromosome 6: 10,980,992–11,044,624) from the DHA GWAS and the
424 LA GWAS. SNPs were selected and harmonised using the same method as in the primary
425 analysis and details are presented in the eMethods. The number of SNPs available for each
426 analysis is presented in eMethods.

427 *5.2.5 MR-Clust analysis to explore heterogeneity in MR instruments*

428 SNPs can influence the outcome in distinct ways (e.g., via distinct biological mechanisms)⁴⁸.
429 This can lead to high levels of heterogeneity between individual SNP-outcome/SNP-
430 exposure causal estimates within an instrument. Therefore, we decided to use MR-Clust⁴⁸ to
431 investigate whether individual causal estimates fell into distinct clusters based on effect
432 magnitude. We used this method when evidence of association was consistent between

433 cohort and MR analyses but there was strong evidence of heterogeneity in the latter.

434 Functional annotations of the genomic loci associated with identified clusters was obtained
435 from FUMAGWAS (<https://fuma.ctglab.nl>). See further details in eMethods.

436 *5.2.6 Multivariable Mendelian Randomisation analysis*

437 MVMR⁶⁵ is an extension of MR that estimates the *direct effect* of each exposure on the
438 outcome, rather than the overall total effect of the exposures (eFigure 2 of the supplement).
439 We conducted a MVMR analysis to estimate the individual direct causal effects of total n-3
440 and n-6 PUFAs on the biomarkers of inflammation independently of each other. See further
441 details in eMethods.

442 5.3 Software

443 Cohort analyses were performed using STATA version 17.0. All other analyses were
444 performed in R Software version 4.1.0.

445

446

447

448

449

450

451

452

453

454

455

456

457

458 References

- 459 1. Videla LA, Hernandez-Rodas MC, Metherel AH, Valenzuela R. Influence of the nutritional
460 status and oxidative stress in the desaturation and elongation of n-3 and n-6 polyunsaturated fatty
461 acids: Impact on non-alcoholic fatty liver disease. *Prostaglandins, Leukotrienes and Essential Fatty
462 Acids* 2022; **181**: 102441.
- 463 2. Collaborators GRF. Global burden of 87 risk factors in 204 countries and territories, 1990-
464 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020; **396**: 1223-49.
- 465 3. Calder PC, Albers R, Antoine JM, et al. Inflammatory Disease Processes and Interactions with
466 Nutrition. *British Journal of Nutrition* 2009; **101**: 1-45.
- 467 4. Calabrò P, Golia E, Yeh ET. *CRP and the risk of atherosclerotic events*. Seminars in
468 Immunopathology; 2009: Springer; 2009. p. 79-94.
- 469 5. Calabro P, Golia E, TH Yeh E. Role of C-reactive protein in acute myocardial infarction and
470 stroke: possible therapeutic approaches. *Current Pharmaceutical Biotechnology* 2012; **13**: 4-16.
- 471 6. Sabaawy HE, Ryan BM, Khiabani H, Pine SR. JAK/STAT of all trades: linking inflammation
472 with cancer development, tumor progression and therapy resistance. *Carcinogenesis* 2021; **42**: 1411-
473 9.
- 474 7. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk
475 of cancer metastasis: a study of incident cancers during randomised controlled trials. *The Lancet*
476 2012; **379**: 1591-601.
- 477 8. Rothwell PM, Fowkes FGR, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin
478 on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.
479 *The Lancet* 2011; **377**: 31-41.
- 480 9. Connelly MA, Otvos JD, Shalurova I, Playford MP, Mehta NN. GlycA, a novel biomarker of
481 systemic inflammation and cardiovascular disease risk. *Journal of Translational Medicine* 2017; **15**:
482 219.
- 483 10. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major
484 depression. *Biol Psychiatry* 2010; **67**: 446-57.
- 485 11. Fries GR, Walss-Bass C, Bauer ME, Teixeira AL. Revisiting inflammation in bipolar disorder.
486 *Pharmacology Biochemistry and Behavior* 2019; **177**: 12-9.
- 487 12. Oliveira J, Oliveira-Maia A, Tamouza R, Brown A, Leboyer M. Infectious and immunogenetic
488 factors in bipolar disorder. *Acta Psychiatrica Scandinavica* 2017; **136**: 409-23.
- 489 13. Currenti W, Godos J, Alanazi AM, et al. Dietary Fats and Cardio-Metabolic Outcomes in a
490 Cohort of Italian Adults. *Nutrients* 2022; **14**: 4294.
- 491 14. El-Badry AM, Graf R, Clavien PA. Omega 3 - Omega 6: What is right for the liver? *J Hepatol*
492 2007; **47**: 718-25.
- 493 15. Miles EA, Childs CE, Calder PC. Long-Chain Polyunsaturated Fatty Acids (LCPUFAs) and the
494 Developing Immune System: A Narrative Review. *Nutrients* 2021; **13**.
- 495 16. Sampath H, Ntambi JM. Polyunsaturated fatty acid regulation of gene expression. *Nutr Rev*
496 2004; **62**: 333-9.
- 497 17. Sokoła-Wysoczańska E, Wysoczański T, Wagner J, et al. Polyunsaturated Fatty Acids and
498 Their Potential Therapeutic Role in Cardiovascular System Disorders-A Review. *Nutrients* 2018; **10**.
- 499 18. Burns-Whitmore B, Froyen E, Heskey C, Parker T, San Pablo G. Alpha-Linolenic and Linoleic
500 Fatty Acids in the Vegan Diet: Do They Require Dietary Reference Intake/Adequate Intake Special
501 Consideration? *Nutrients* 2019; **11**.
- 502 19. Hodge L, Salome CM, Peat JK, Haby MM, Xuan W, Woolcock AJ. Consumption of oily fish and
503 childhood asthma risk. *Medical Journal of Australia* 1996; **164**: 137-40.
- 504 20. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. *Am J
505 Clin Nutr* 2006; **83**: 1505s-19s.
- 506 21. Chaddha A, Eagle KA. Omega-3 fatty acids and heart health. *Circulation* 2015; **132**: e350-e2.

- 507 22. Kris-Etherton PM, Fleming JA. Emerging nutrition science on fatty acids and cardiovascular
508 disease: nutritionists' perspectives. *Adv Nutr* 2015; **6**: 326s-37s.
- 509 23. Pischon T, Hankinson SE, Hotamisligil GKS, Rifai N, Willett WC, Rimm EB. Habitual Dietary
510 Intake of n-3 and n-6 Fatty Acids in Relation to Inflammatory Markers Among US Men and Women.
511 *Circulation* 2003; **108**: 155-60.
- 512 24. Lopez-Garcia E, Schulze MB, Meigs JB, et al. Consumption of trans fatty acids is related to
513 plasma biomarkers of inflammation and endothelial dysfunction. *The Journal of Nutrition* 2005; **135**:
514 562-6.
- 515 25. Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Glaser R. Omega-3 supplementation
516 lowers inflammation and anxiety in medical students: a randomized controlled trial. *Brain, Behavior,
517 and Immunity* 2011; **25**: 1725-34.
- 518 26. Hu FB, Manson JE. Omega-3 Fatty Acids and Secondary Prevention of Cardiovascular
519 Disease—Is It Just a Fish Tale?: Comment on “Efficacy of Omega-3 Fatty Acid Supplements
520 (Eicosapentaenoic Acid and Docosahexaenoic Acid) in the Secondary Prevention of Cardiovascular
521 Disease”. *Archives of Internal Medicine* 2012; **172**: 694-6.
- 522 27. Goldberg RJ, Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated
523 fatty acid supplementation for inflammatory joint pain. *Pain* 2007; **129**: 210-23.
- 524 28. MacLean CH, Mojica WA, Morton SC, et al. Effects of omega-3 fatty acids on lipids and
525 glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease,
526 rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis: Summary.
527 *AHRQ Evidence Report Summaries*. Rockville (MD): Agency for Healthcare Research and Quality (US);
528 2004.
- 529 29. Kelley DS, Taylor PC, Nelson GJ, Mackey BE. Arachidonic acid supplementation enhances
530 synthesis of eicosanoids without suppressing immune functions in young healthy men. *Lipids* 1998;
531 **33**: 125-30.
- 532 30. Thies F, Miles EA, Nebe-von-Caron G, et al. Influence of dietary supplementation with long-
533 chain n-3 or n-6 polyunsaturated fatty acids on blood inflammatory cell populations and functions
534 and on plasma soluble adhesion molecules in healthy adults. *Lipids* 2001; **36**: 1183-93.
- 535 31. Kakutani S, Ishikura Y, Tateishi N, et al. Supplementation of arachidonic acid-enriched oil
536 increases arachidonic acid contents in plasma phospholipids, but does not increase their metabolites
537 and clinical parameters in Japanese healthy elderly individuals: a randomized controlled study. *Lipids
538 in Health and Disease* 2011; **10**: 1-12.
- 539 32. Shen S, Gong C, Jin K, Zhou L, Xiao Y, Ma L. Omega-3 Fatty Acid Supplementation and
540 Coronary Heart Disease Risks: A Meta-Analysis of Randomized Controlled Clinical Trials. *Front Nutr*
541 2022; **9**: 809311.
- 542 33. Gracious BL, Chirieac MC, Costescu S, Finucane TL, Youngstrom EA, Hibbeln JR. Randomized,
543 placebo-controlled trial of flax oil in pediatric bipolar disorder. *Bipolar Disorders* 2010; **12**: 142-54.
- 544 34. Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in
545 mania and bipolar depression. *J Clin Psychiatry* 2012; **73**: 81-6.
- 546 35. Bazinet RP, Layé S. Polyunsaturated fatty acids and their metabolites in brain function and
547 disease. *Nature Reviews Neuroscience* 2014; **15**: 771-85.
- 548 36. Spiller GA. *Handbook of Lipids in Human Nutrition*. Boca Raton (FL): CRC press; 1995.
- 549 37. Wei Y, Meng Y, Li N, Wang Q, Chen L. The effects of low-ratio n-6/n-3 PUFA on biomarkers of
550 inflammation: a systematic review and meta-analysis. *Food Funct* 2021; **12**: 30-40.
- 551 38. Innes JK, Calder PC. Omega-6 fatty acids and inflammation. *Prostaglandins, Leukotrienes and
552 Essential Fatty Acids* 2018; **132**: 41-8.
- 553 39. Ferrucci L, Cherubini A, Bandinelli S, et al. Relationship of plasma polyunsaturated fatty acids
554 to circulating inflammatory markers. *The Journal of Clinical Endocrinology & Metabolism* 2006; **91**:
555 439-46.
- 556 40. Sanderson E, Glymour MM, Holmes MV, et al. Mendelian randomization. *Nature Reviews
557 Methods Primers* 2022; **2**: 1-21.

- 558 41. Würtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M. Quantitative
559 Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic
560 Technologies. *American journal of epidemiology* 2017; **186**: 1084-96.
- 561 42. Soininen P, Kangas AJ, Würtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic
562 resonance metabolomics in cardiovascular epidemiology and genetics. *Circulation: cardiovascular
563 genetics* 2015; **8**: 192-206.
- 564 43. Borges MC, Haycock PC, Zheng J, et al. Role of circulating polyunsaturated fatty acids on
565 cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid genetic
566 association data from over 114,000 UK Biobank participants. *BMC Medicine* 2022; **20**.
- 567 44. Clayton GL, Borges MC, Lawlor DA. From menarche to menopause: the impact of
568 reproductive factors on the metabolic profile of over 65,000 women. *medRxiv* 2022:
569 <https://doi.org/10.1101/2022.04.17.22273947>
- 570 45. Ligthart S, Vaez A, Vösa U, et al. Genome analyses of > 200,000 individuals identify 58 loci for
571 chronic inflammation and highlight pathways that link inflammation and complex disorders. *The
572 American Journal of Human Genetics* 2018; **103**: 691-706.
- 573 46. Ahluwalia TS, Prins BP, Abdollahi M, et al. Genome-wide association study of circulating
574 interleukin 6 levels identifies novel loci. *Hum Mol Genet* 2021; **30**: 393-409.
- 575 47. Mounier N. Bias correction for inverse variance weighting Mendelian randomization. *Genetic
576 Epidemiology* 2023; **47**: 314-31.
- 577 48. Foley CN, Mason AM, Kirk PDW, Burgess S. MR-Clust: clustering of genetic variants in
578 Mendelian randomization with similar causal estimates. *Bioinformatics* 2020; **37**: 531-41.
- 579 49. Haycock PC, Borges MC, Burrows K, et al. The association between genetically elevated
580 polyunsaturated fatty acids and risk of cancer. *EBioMedicine* 2023; **91**: 104510.
- 581 50. Simopoulos AP, Cleland LGCE. Omega-6/omega-3 essential fatty acid ratio: The Scientific
582 Evidence. *Scandinavian Journal of Nutrition* 2004; **48**: 49-50.
- 583 51. Wei Y, Meng Y, Li N, Wang Q, Chen L. The effects of low-ratio n-6/n-3 PUFA on biomarkers of
584 inflammation: a systematic review and meta-analysis. *Food & Function* 2021; **12**: 30-40.
- 585 52. Chen Y, Lu T, Pettersson-Kymmer U, et al. Genomic atlas of the plasma metabolome
586 prioritizes metabolites implicated in human diseases. *Nature Genetics* 2023; **55**: 44-53.
- 587 53. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. *J Am Coll
588 Nutr* 2002; **21**: 495-505.
- 589 54. Bouzan C, Cohen JT, Connor WE, et al. A quantitative analysis of fish consumption and stroke
590 risk. *Am J Prev Med* 2005; **29**: 347-52.
- 591 55. Siriwardhana N, Kalupahana NS, Moustaid-Moussa N. Health benefits of n-3 polyunsaturated
592 fatty acids: eicosapentaenoic acid and docosahexaenoic acid. *Adv Food Nutr Res* 2012; **65**: 211-22.
- 593 56. Boyd A, Golding J, Macleod J, et al. Cohort Profile: the 'children of the 90s'--the index
594 offspring of the Avon Longitudinal Study of Parents and Children. *Int J Epidemiol* 2013; **42**: 111-27.
- 595 57. Fraser A, Macdonald-Wallis C, Tilling K, et al. Cohort Profile: the Avon Longitudinal Study of
596 Parents and Children: ALSPAC mothers cohort. *Int J Epidemiol* 2013; **42**: 97-110.
- 597 58. Northstone K, Lewcock M, Groom A, et al. The Avon Longitudinal Study of Parents and
598 Children (ALSPAC): an update on the enrolled sample of index children in 2019. *Wellcome Open Res*
599 **2019**; **4**: 51.
- 600 59. Soininen P, Kangas AJ, Würtz P, et al. High-throughput serum NMR metabolomics for cost-
601 effective holistic studies on systemic metabolism. *Analyst* 2009; **134**: 1781-5.
- 602 60. Soininen P, Kangas AJ, Wurtz P, et al. High-throughput serum NMR metabolomics for cost-
603 effective holistic studies on systemic metabolism. *Analyst* 2009; **134**: 1781-5.
- 604 61. Inouye M, Kettunen J, Soininen P, et al. Metabonomic, transcriptomic, and genomic variation
605 of a population cohort. *Mol Syst Biol* 2010; **6**: 441.
- 606 62. Goulding N, Goudswaard L, Hughes D, et al. Inflammation proteomics datasets in the ALSPAC
607 cohort [version 1; peer review: 1 approved, 1 approved with reservations]. *Wellcome Open Research*
608 **2022**; **7**.

- 609 63. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization:
610 using genes as instruments for making causal inferences in epidemiology. *Statistics in Medicine*
611 2008; **27**: 1133-63.
- 612 64. Crick D, Sanderson E, Jones H, et al. Glycoprotein Acetyls and Depression: testing for
613 directionality and potential causality using longitudinal data and Mendelian randomization analyses.
614 medRxiv; 2022.
- 615 65. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable
616 Mendelian randomization in the single-sample and two-sample summary data settings. *International*
617 *Journal of Epidemiology* 2019; **48**: 713-27.

618

619

620

621 **Acknowledgements**

622 This work was carried out using the computational facilities of the Advanced Computing
623 Research Centre, University of Bristol - <http://www.bristol.ac.uk/acrc/>.

624 We are extremely grateful to all the families who took part in this study, the midwives for
625 their help in recruiting them, and the whole ALSPAC team, which includes interviewers,
626 computer and laboratory technicians, clerical workers, research scientists, volunteers,
627 managers, receptionists, and nurses.

628

629 **Contributions**

630 **Daisy C.P. Crick:** Conceptualization, Methodology, Investigation, Writing – original draft,
631 Writing – review & editing. **Hannah Jones:** Writing – Conceptualization, Supervision,
632 Methodology, review & editing. **Sarah Halligan:** Supervision, Writing – review & editing.
633 **Golam M. Khandaker:** Conceptualization, Methodology, Supervision, Writing – review &
634 editing. **George Davey Smith:** Methodology, Writing – review & editing.

635 Correspondence to Daisy Crick

636

637 **Competing interests**

638

639 Authors declare no relevant potential conflict of interest related to the material presented
640 in the article.

641

642 **Data availability**

643 Data needed to evaluate the conclusions presented in this paper are provided in the
644 manuscript and/or the supplementary material. Additionally ALSPAC data can be requested
645 from the ALSPAC executive committee and reasonable requests from bona fide researchers.
646 GWAS data is publicly available using the OpenGWAS website (<https://gwas.mrcieu.ac.uk>)

647

648 **Code availability**

649 Code for data management and statistical analysis has been made available in [daisycrick](https://daisycrick.github.com)
650 [github.com](https://daisycrick.github.com).

651

652

653 **Funding**

654 The UK Medical Research Council and Wellcome (Grant ref.: [217065/Z/19/Z](#)) and
655 the University of Bristol provide core support for ALSPAC. This publication is the work of the
656 authors and DC will serve as guarantor for the contents of this paper. A comprehensive list
657 of grants funding is available on the ALSPAC website
658 (<http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf>); This
659 research was specifically funded by Wellcome Trust and MRC (core) (Grant
660 ref.: [76467/Z/05/Z](#)), MRC (Grant ref.: [MR/L022206/1](#)) and Wellcome Trust (Grant
661 ref.: [8426812/Z/07/Z](#)).

662 This work was supported in part by the GW4 BIOMED DTP (D.C., [MR/N0137941/1](#)), awarded
663 to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council
664 (MRC)/UKRI.

665 GDS, GMK and HJ work within the MRC Integrative Epidemiology Unit at the University of
666 Bristol, which is supported by the Medical Research Council (MC_UU_00011/1).

667 GMK acknowledges funding support from the Wellcome Trust (grant no: [201486/Z/16/Z](#) and
668 [201486/B/16/Z](#)), the UK Medical Research Council (grant no: [MC_UU_00032/06](#);
669 [MR/W014416/1](#); and [MR/S037675/1](#)), and the UK National Institute of Health Research
670 Bristol Biomedical Research Centre (grant no: [NIHR 203315](#)).

671 HJ is supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and
672 Weston NHS Foundation Trust and the University of Bristol. The views expressed are those
673 of the author(s) and not necessarily those of the NIHR or the Department of Health and
674 Social Care.

675

676

677

678

679

680

681

682

683

684

685

686 **Tables**

687

Table 1: Median and interquartile range of exposure and outcome data (n = 2748)

	Median (IQR)	Range
GlycA (mmol/L)	1.22 (1.12-1.34)	0.84-2.25
CRP (mmol/l)	0.87 (0.39-2.29)	0.1-70.05
IL-6 (NPX log2)	3.32 (2.96-3.85)	1.82-9.86
DHA	0.11 (0.09-0.13)	0.04-0.32
LA	2.31 (1.98-2.68)	0.89-4.91
Total n-3 PUFAs	0.29 (0.24-0.34)	0.07-0.80
Total n-6 PUFAs	2.85 (2.48-3.28)	1.23-5.82

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710 **Figures**

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735




Figure 1: Schematic representation of polyunsaturated fatty acid biosynthesis in mammals adapted from Videla 2022 ¹




Figure 2: Association between fatty acids and inflammatory biomarkers using cohort data after adjusting estimates for household social class, maternal highest education qualification, maternal and paternal smoking status during pregnancy, offspring sex and age and status at 24 year clinic




Figure 3: Association between fatty acids and inflammatory biomarkers stratified by sex using cohort data after adjusting estimates for household social class, maternal highest education qualification, maternal and paternal smoking status during pregnancy, offspring sex and age and status at 24 year clinic




Figure 4: Univariable causal effect of fatty acids on Inflammation




Figure 5: Multivariable Mendelian randomization analysis of direct effect of Omega-3 and Omega-6 on Inflammation